Tagged with

Pharma Legal Handbook The low-down on the situation regarding product liability in Belgium. Prepared in association with ALTIUS, a leading law firm in Belgium, this is an extract from The Pharma Legal Handbook: Belgium, available to purchase here for USD 99.   1. What types of liability are recognized in your jurisdiction? Belgian law distinguishes two…

Pharma Legal Handbook The key facts about regulatory reforms in Belgium. Prepared in association with ALTIUS, a leading law firm in Belgium, this is an extract from The Pharma Legal Handbook: Belgium, available to purchase here for USD 99.   1. Are there proposals for reform or significant change to the healthcare system? As of recently,…

Pharma Legal Handbook Keen to learn more about patents & trademarks in Belgium? Read on! Prepared in association with ALTIUS, a leading law firm in Belgium, this is an extract from The Pharma Legal Handbook: Belgium, available to purchase here for USD 99.   1. What are the basic requirements to obtain patent and trademark protection?…

Report PharmaBoardroom had the opportunity to sit down with over six hundred key stakeholders in the life sciences industry across fifteen different countries in 2019. The culmination of time spent in these countries and the insights gained from the interviews we conducted resulted in the publishing of thirteen country reports. Here…

Top 5 In 2019 PharmaBoardroom had the exclusive opportunity to speak with executives that are heading up some of European pharma’s top companies. These stakeholders provided insights into their visions and strategies for success and how they are embracing innovation as they forge ahead.      David Loew, Executive Vice President, Sanofi…

Opinion 2019 was a year of innovation and disruption in the life sciences industry. From artificial intelligence to cell and gene therapy, and from generics and biosimilars to geopolitics and healthcare reform, PharmaBoardroom is proud to have collaborated with industry thought leaders to publish their insights on the year’s top trends…

Hungary Péter Ferdinandy and Zsuzsanna Helyes, President and Secretary General of the Hungarian Society for Experimental and Clinical Pharmacology (HUPHAR), share their insights about the role of the society, the R&D capabilities of the Hungarian pharmaceutical industry, the ability of local players to bring innovations to the market, and the future…

Czech Republic Emmanuelle Boishardy joined GSK in France 20 years ago. In 2017, she embarked on her first assignment as General Manager – in the Czech affiliate. She recounts how she adapted to her new position in a foreign country and turned the affiliate around by overhauling compliance processes and successful launches…

Hungary József Béres, President of Béres and Ferenc Major, CEO, share their insights on the history of the company, its performance and approach to creating brand awareness, the importance of R&D in their internationalization strategy, and the long-term vision of the company.   Healthcare elements are increasingly expensive, and the burden…

CEE With a footprint of over 20 years in the Czech Republic, Gedeon Richter’s affiliate here is a key pillar to the company’s success in the Central Eastern European region. Corina Croitoru, Managing Director for the Czech Republic and Slovakia, evaluates the challenges that come with bringing to market medicines on…

Hungary Dr. András Szabó, CEO of Szinapszis, a Hungarian market research and consulting agency specialized in the health industry, offers his expert insights on the key challenges and trends shaping the country’s pharma and healthcare ecosystem. Furthermore, Szabó highlights the offering Szinapszis can deliver as a partner of choice to both…

Canada Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to better tackle rare diseases in Canada.   Especially in smaller provinces, it’s virtually impossible to predictably manage the affordability and accessibility of drugs necessary to treat rare disease Around the world, rare diseases are becoming easier…